EA201990427A1 - RNAi AGENTS AGAINST INFECTION CAUSED BY HEPATITIS B VIRUS - Google Patents
RNAi AGENTS AGAINST INFECTION CAUSED BY HEPATITIS B VIRUSInfo
- Publication number
- EA201990427A1 EA201990427A1 EA201990427A EA201990427A EA201990427A1 EA 201990427 A1 EA201990427 A1 EA 201990427A1 EA 201990427 A EA201990427 A EA 201990427A EA 201990427 A EA201990427 A EA 201990427A EA 201990427 A1 EA201990427 A1 EA 201990427A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- hbv
- agents
- hepatitis
- virus
- gene expression
- Prior art date
Links
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Описаны композиции и способы ингибирования экспрессии гена вируса гепатита B. Описаны агенты РНК-интерференции (РНКи) для ингибирования экспрессии гена вируса гепатита B. Агенты РНКи против ВГВ, описанные в настоящем документе, могут быть нацелены на клетки, такие как гепатоциты, например, с использованием конъюгированных нацеливающих лигандов. Также описаны фармацевтические композиции, содержащие один или более агентов РНКи против ВГВ и необязательно один или более дополнительных терапевтических средств. Доставка описанных агентов РНКи против ВГВ в инфицированную печень in vivo обеспечивает ингибирование экспрессии гена ВГВ и лечение заболеваний и состояний, связанных с инфекцией ВГВ.Compositions and methods for inhibiting hepatitis B virus gene expression are described. RNA interference agents (RNAi) for inhibiting hepatitis B gene expression are described. Anti-HBV RNA agents described herein can target cells such as hepatocytes, for example, with using conjugated targeting ligands. Also described are pharmaceutical compositions containing one or more anti-HBV RNA agents and optionally one or more additional therapeutic agents. In vivo delivery of the described anti-HBV RNAi agents to the infected liver in vivo provides inhibition of HBV gene expression and treatment of diseases and conditions associated with HBV infection.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762540639P | 2017-08-03 | 2017-08-03 | |
PCT/US2017/045446 WO2018027106A2 (en) | 2016-08-04 | 2017-08-04 | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION |
Publications (1)
Publication Number | Publication Date |
---|---|
EA201990427A1 true EA201990427A1 (en) | 2019-08-30 |
Family
ID=67734935
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201990427A EA201990427A1 (en) | 2017-08-03 | 2017-08-04 | RNAi AGENTS AGAINST INFECTION CAUSED BY HEPATITIS B VIRUS |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA201990427A1 (en) |
-
2017
- 2017-08-04 EA EA201990427A patent/EA201990427A1/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019500245A1 (en) | RNAi AGENTS FOR HEPATITIS B VIRUS INFECTION | |
WO2017027350A3 (en) | Rnai therapy for hepatitis b virus infection | |
MX2021009495A (en) | Rnai agents for hepatitis b virus infection. | |
ZA202106265B (en) | Compositions and methods for inhibiting gene expression of lpa | |
EA202191537A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITION OF HEPATITIS B VIRUS GENE EXPRESSION | |
EA202090514A1 (en) | ANTI-VIRAL AGAINST HEPATITIS IN | |
EA201491179A1 (en) | 2 ', 4'-DIFFOROR-2'-METHYL SUBSTITUTED NUCLEOSIDE DERIVATIVES AS AN INHIBITORS REPLICATION RNA HEPATITIS C VIRUS | |
MX2022009352A (en) | Nucleotide hemi-sulfate salt for the treatment of hepatitis c virus. | |
EA201791535A1 (en) | NEW CONNECTION 4'-TIONOUCLEOSIDE, AND ALSO THE WAY OF ITS OBTAINING, ITS PHARMACEUTICAL COMPOSITION AND APPLICATION | |
EA201792103A1 (en) | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF HIF2ALPH GENES | |
NZ628515A (en) | Antiviral compounds with a dibenzooxaheterocycle moiety | |
JO3281B1 (en) | Benzofuran Compounds for the Treatment of Hepatitis C Virus Infections | |
PH12021550287A1 (en) | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | |
EA201990427A1 (en) | RNAi AGENTS AGAINST INFECTION CAUSED BY HEPATITIS B VIRUS | |
EA202192191A1 (en) | RNAi AGENTS AGAINST HEPATITIS B VIRUS INFECTION | |
JO3769B1 (en) | RNAi Therapy for Hepatitis B Virus Infection | |
AR109293A1 (en) | IRN AGENTS FOR INFECTION WITH THE HEPATITIS B VIRUS | |
EA202090234A1 (en) | RNAi MEANS FOR INHIBITING ALPHA-ENaC EXPRESSION AND METHODS OF APPLICATION | |
EA201892004A1 (en) | ANTIVIRAL AGENTS FOR THE TREATMENT OF HEPATITIS B | |
EA201891427A1 (en) | TARGET LIGANDS FOR THERAPEUTIC COMPOUNDS |